ABSTRACT

Objective

To evaluate the cost-effectiveness of trifluridine/tipiracil (FTD/TPI) compared with best supportive care (BSC) for the treatment of patients with metastatic gastric cancer(mGC), including gastroesophageal junction adenocarcinoma(GEJ), who have received at least two prior therapies for metastatic disease and are eligible for third-line treatment, in Greece.

Methods

A partitioned survival model was locally adapted from a public payer perspective over a 10-year time horizon. Clinical, safety and utility data were extracted from literature. Resource consumption data obtained from a panel of local experts using a questionnaire developed for the study was combined with unit costs obtained from official sources. All costs reflect the year 2020 (€). Outcomes of the model were patients’ life years (LYs) and quality-adjusted life years (QALYs), total costs and incremental cost-effectiveness ratio (ICER) per QALY and LY gained.

Results

The total cost per patient was estimated to be €6,965 for FTD/TPI and €1,906 for BSC, while FTD/TPI was associated with 0.180 and 0.107 increments in LYs and QALYs, respectively, compared with BSC, resulting in an ICER of €47,144 per QALY gained and €28,112 per LY gained.

Conclusion

FTD/TPI was estimated to be a cost-effective treatment option for eligible third line mGC patients, including GEJ in Greece.

中文翻译：

---

在先前在希腊接受过治疗的患者中，曲氟尿苷/替吡嘧啶作为转移性胃癌（包括胃食管交界处腺癌）的三线治疗的成本效益

摘要

客观的

评估曲氟尿苷/替吡嘧啶 (FTD/TPI) 与最佳支持治疗 (BSC) 相比治疗转移性胃癌 (mGC) 患者的成本效益，包括胃食管结合部腺癌 (GEJ)，他们至少接受过两次治疗转移性疾病的先前治疗，并有资格在希腊进行三线治疗。

方法

在 10 年的时间范围内，从公共支付者的角度对分区生存模型进行了本地调整。从文献中提取临床、安全性和实用性数据。使用为研究开发的问卷从当地专家小组获得的资源消耗数据与从官方来源获得的单位成本相结合。所有成本均反映 2020 年（欧元）。该模型的结果是患者的生命年 (LYs) 和质量调整生命年 (QALYs)、每 QALY 和 LY 获得的总成本和增量成本效益比 (ICER)。

结果

FTD/TPI 每位患者的总成本估计为 6,965 欧元，BSC 为 1,906 欧元，而与 BSC 相比，FTD/TPI 分别与 LYs 和 QALYs 增加 0.180 和 0.107 相关，导致 ICER 为 47,144 欧元每 QALY 收益，每 LY 收益 28,112 欧元。

结论

FTD/TPI 估计是符合条件的三线 mGC 患者的一种具有成本效益的治疗选择，包括希腊的 GEJ。